PRIA Logo™
117-hr-941117th CongressWALLET

TRANSPLANT Act of 2021

Sponsored By: Representative Matsui, Doris O. [D-CA-7]

Became Law

Summary

Modernizes and funds U.S. stem-cell and regenerative medicine programs. The law reauthorizes the C.W. Young Cell Transplantation Program, updates its scientific scope, and builds NIH–FDA coordination and workforce planning to expand access to cord blood and adult stem‑cell therapies.

Show full summary
  • Patients and families: Requires regular scientific reviews at least every 2 years to consider adding adult stem cells and birthing tissues to the program. The Secretary must complete the second review and send recommendations to Congress by June 30, 2025.
  • Researchers and regulators: Directs the NIH Director to consult across NIH and with the Food and Drug Administration to advance adult stem cells, autologous cells, tissue engineering, gene therapies, and genetically modified cell products.
  • Workforce and industry: Orders the Government Accountability Office to deliver a workforce assessment in 2 years that maps current jobs, gaps, training availability including good manufacturing practice training, and offers recommendations to boost capacity.
  • Program funding and operations: Authorizes $31.0 million per year for the transplantation program and $23.0 million per year for cord blood activities for fiscal years 2022 through 2026.

*Authorizes about $54.0 million per year for these programs through 2026, increasing federal spending over that period.*

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

3 provisions identified: 3 benefits, 0 costs, 0 mixed.

Funding keeps transplant and cord blood programs

The law authorizes $31.009 million each year for the C.W. Bill Young Cell Transplantation Program for FY 2022–2026. It also authorizes $23 million each year for the national cord blood inventory for FY 2022–2026. This funding helps patients who need marrow or cord blood transplants. It also supports cord blood banks and transplant centers.

More oversight and science reviews for transplants

The Secretary must meet with the program’s advisory council at least two times each year. The law requires a science review on adult stem cells and birthing tissues at least every two years. The second review must finish and send recommendations to Congress by June 30, 2025. The program goal now clearly prioritizes collecting high‑quality cord blood units.

NIH works with FDA on regenerative medicine

The law directs the NIH Director to keep consulting with NIH and FDA experts on regenerative medicine. It covers adult stem cells, autologous cells, tissue engineering, human cell and tissue products, gene therapies, and modified cells. This coordination starts upon enactment to help move safe therapies forward.

Sponsors & CoSponsors

Sponsor

Matsui, Doris O. [D-CA-7]

CA • D

Cosponsors

  • Rep. Bilirakis, Gus M. [R-FL-12]

    FL • R

    Sponsored 2/8/2021

  • Rep. Pingree, Chellie [D-ME-1]

    ME • D

    Sponsored 2/8/2021

  • Rep. Hudson, Richard [R-NC-9]

    NC • R

    Sponsored 2/22/2021

  • Rep. Brownley, Julia [D-CA-26]

    CA • D

    Sponsored 2/22/2021

  • Rep. Butterfield, G. K. [D-NC-1]

    NC • D

    Sponsored 2/23/2021

  • Rep. Fitzpatrick, Brian K. [R-PA-1]

    PA • R

    Sponsored 2/25/2021

  • Rep. Scanlon, Mary Gay [D-PA-5]

    PA • D

    Sponsored 2/25/2021

  • Rep. Emmer, Tom [R-MN-6]

    MN • R

    Sponsored 2/25/2021

  • Rep. Aguilar, Pete [D-CA-33]

    CA • D

    Sponsored 2/26/2021

  • Rep. Rush, Bobby L. [D-IL-1]

    IL • D

    Sponsored 2/26/2021

  • Rep. Schrader, Kurt [D-OR-5]

    OR • D

    Sponsored 3/2/2021

  • Rep. Napolitano, Grace F. [D-CA-31]

    CA • D

    Sponsored 3/8/2021

  • Rep. Craig, Angie [D-MN-2]

    MN • D

    Sponsored 3/8/2021

  • Rep. Chu, Judy [D-CA-28]

    CA • D

    Sponsored 3/8/2021

  • Rep. Dean, Madeleine [D-PA-4]

    PA • D

    Sponsored 3/8/2021

  • Rep. Trone, David J. [D-MD-6]

    MD • D

    Sponsored 3/16/2021

  • Rep. Hayes, Jahana [D-CT-5]

    CT • D

    Sponsored 3/16/2021

  • Rep. Jones, Mondaire [D-NY-17]

    NY • D

    Sponsored 3/17/2021

  • Rep. Swalwell, Eric [D-CA-14]

    CA • D

    Sponsored 3/17/2021

  • Rep. McClintock, Tom [R-CA-5]

    CA • R

    Sponsored 3/29/2021

  • Rep. Crist, Charlie [D-FL-13]

    FL • D

    Sponsored 3/29/2021

  • Rep. Young, Don [R-AK-At Large]

    AK • R

    Sponsored 3/29/2021

  • Rep. Omar, Ilhan [D-MN-5]

    MN • D

    Sponsored 4/13/2021

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation